[1]
|
Dalbeth, N., Gosling, A.L., Gaffo, A., et al. (2021) Gout. The Lancet, 397, 1843-1855.
https://doi.org/10.1016/S0140-6736(21)00569-9
|
[2]
|
罗亚丹, 袁立英, 陆怡德, 等. 成人患者血尿酸水平调查及相关影响因素分析[J]. 内科理论与实践, 2023, 18(3): 141-145.
|
[3]
|
Piao, W., Zhao, L., Yang, Y., Fang, H., Ju, L., Cai, S. and Yu, D. (2022) The Prevalence of Hyperuricemia and Its Correlates among Adults in China: Results from CNHS 2015-2017. Nutrients, 14, 4095.
https://doi.org/10.3390/nu14194095
|
[4]
|
丁贤彬, 陈莉玲, 唐文革, 等. 重庆市30-79岁居民高尿酸血症患病率及相关因素分析[J]. 实用预防医学, 2023, 30(8): 897-901.
|
[5]
|
Sun, Y., Sun, J., Zhang, P., Zhong, F., Cai, J. and Ma, A. (2019) Association of Dietary Fiber Intake with Hyperuricemia in U.S. Adults. Food & Function, 10, 4932-4940. https://doi.org/10.1039/C8FO01917G
|
[6]
|
Khanna, D., Fitzgerald, J.D., Khanna, P.P., et al. (2012) 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care & Research, 64, 1431-1446. https://doi.org/10.1002/acr.21772
|
[7]
|
范俊, 柏晓松, 熊世力. 高尿酸血症患者URAT1基因rs524023位点多态性检测及临床意义[J]. 海南医学, 2023, 34(7): 987-990.
|
[8]
|
Enomoto, A., Kimura, H., Chairoungdua, A., Shigeta, Y., Jutabha, P., Cha, S.H., Hosoyamada, M., Takeda, M., Sekine, T., Igarashi, T., et al. (2002) Molecular Identification of a Renal Urate Anion Exchanger That Regulates Blood Urate Levels. Nature, 417, 447-452. https://doi.org/10.1038/nature742
|
[9]
|
Dalbeth, N., Merriman, T.R. and Stamp, L.K. (2016) Gout. The Lancet, 388, 2039-2052.
https://doi.org/10.1016/S0140-6736(16)00346-9
|
[10]
|
Otani, N., Ouchi, M., Kudo, H., Tsuruoka, S., Hisatome, I. and Anzai, N. (2020) Recent Approaches to Gout Drug Discovery: An Update. Expert Opinion on Drug Discovery, 15, 943-954.
https://doi.org/10.1080/17460441.2020.1755251
|
[11]
|
Barkas, F., Elisaf, M., Liberopoulos, E., Kalaitzidis, R. and Liamis, G. (2018) Uric Acid and Incident Chronic Kidney Disease in Dyslipidemic Individuals. Current Medical Re-search and Opinion, 34, 1193-1199.
https://doi.org/10.1080/03007995.2017.1372157
|
[12]
|
Nakayama, A., Matsuo, H., Nakaoka, H., Nakamura, T., Nakashima, H., Takada, Y., Oikawa, Y., Takada, T., Sakiyama, M., Shimizu, S., et al. (2014) Common Dysfunctional Variants of ABCG2 Have Stronger Impact on Hyperuricemia Progression than Typical Environmental Risk Factors. Scientific Reports, 4, Article No. 5227.
https://doi.org/10.1038/srep05227
|
[13]
|
雷国大. 非布司他与苯溴马隆、别嘌醇在降尿酸治疗中的有效性和安全性对比分析[J]. 现代诊断与治疗, 2019, 30(9): 1402-1404.
|
[14]
|
Diaz-Torné, C., Perez-Herrero, N. and Perez-Ruiz, F. (2015) New Medications in Development for the Treatment of Hyperuricemia of Gout. Current Opinion in Rheuma-tology, 27, 164-169.
https://doi.org/10.1097/BOR.0000000000000146
|
[15]
|
Shahid, H. and Singh, J.A. (2015) Investigational Drugs for Hyperuricemia. Expert Opinion on Investigational Drugs, 24, 1013-1030. https://doi.org/10.1517/13543784.2015.1051617
|
[16]
|
Tan, P.K., Sha, L., Gunic, E., et al. (2017) Discovery and Characterization of Verinurad, a Potent and Specific Inhibitor of URAT1 for the Treatment of Hyperuricemia and Gout. Scientific Reports, 7, Article No. 665.
https://doi.org/10.1038/s41598-017-00706-7
|
[17]
|
Lee, M.H., Graham, G.G., Williams, K.M. and Day, R.O. (2008) A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout: Was Its Withdrawal from the Market in the Best Interest of Patients? Drug Safety, 31, 643-665.
https://doi.org/10.2165/00002018-200831080-00002
|
[18]
|
Ye, P., Yang, S.M., Zhang, W.L., Lv, Q., Cheng, Q.F., Mei, M., Luo, T., Liu, L.L., Chen, S.M. and Li, Q.F. (2013) Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients with or without Gout: A Systematic Review and Meta-Analysis. Clinical Therapeutics, 35, 180-189. https://doi.org/10.1016/j.clinthera.2012.12.011
|
[19]
|
Ma, J.K. and Zhang, H.B. (2018) The Research Progress of Hyperuricemia and Its Therapeutic Drugs. Guangdong Medical Journal, 39, 262-267.
|
[20]
|
Schumacher, H.R., Becker, M.A., Wortmann, R.L., MacDonald, P.A., Hunt, B., Streit, J., Lademacher, C. and Joseph-Ridge, N. (2008) Effects of Febuxostat versus Allopurinol and Placebo in Reducing Serum Urate in Subjects with Hyperuricemia and Gout: A 28-Week, Phase III, Randomized, Double-Blind, Parallel-Group Trial. Arthritis & Rheumatology, 59, 1540-1548. https://doi.org/10.1002/art.24209
|
[21]
|
王新陆. 关于血浊理论在现代疾病谱系中作用与地位的探讨[J]. 天津中医药, 2011, 28(5): 355-357.
|
[22]
|
沈倩, 李贺, 雷珊珊, 等. 铁皮石斛四妙方对高尿酸血症模型大鼠的降尿酸作用及机制研究[J]. 中国现代应用药学, 2019, 36(2): 157-163.
|
[23]
|
Chen, X., Ge, H.Z., Lei, S.S., et al. (2020) Dendrobium officinalis Six Nostrum Ameliorates Urate Under-Excretion and Protects Renal Dysfunction in Lipid Emul-sion-Induced Hyperuricemic Rats. Biomedicine & Pharmacotherapy, 132, Article ID: 110765. https://doi.org/10.1016/j.biopha.2020.110765
|
[24]
|
熊雯雯, 张红阳, 文乐, 等. 短穗兔耳草提取物对高尿酸血症小鼠黄嘌呤氧化酶和肾脏尿酸转运体的影响研究[J]. 中国新药杂志, 2018, 27(13): 1538-1543.
|
[25]
|
王星, 薛宁, 李洪雷, 等. 防己黄芪汤对高尿酸血症小鼠降尿酸及肾保护作用机制的研究[J]. 中国中药杂志, 2020, 45(21): 5248-5255.
|
[26]
|
丁秀, 程业刚, 王小琴. 防己黄芪汤治疗原发性肾病综合征的Meta分析[J]. 湖南中医杂志, 2018, 34(5): 158.
|
[27]
|
张媛, 徐红. 复方芪苓配方颗粒对尿酸性肾病模型大鼠作用机制研究[J]. 浙江中西医结合杂志, 2020, 30(5): 375-379.
|
[28]
|
蔡唐彦, 肖艳, 郭洁梅, 毛骁, 王建辉, 李保林, 滕方舟, 林建平, 苏友新. 痛风宁对高尿酸血症模型大鼠肾脏尿酸盐转运体表达的影响[J]. 中国实验方剂学杂志, 2020, 26(16): 79-86.
|
[29]
|
李醒, 褚夫江, 蒋诗林, 等. 桑黄乙醇提取物对大鼠尿酸代谢及肠道微生物影响的初步研究[J]. 中国中药杂志, 2021, 46(1): 177-182.
|
[30]
|
Wu, J., Wei, Z., Cheng, P., et al. (2020) Rhein Modulates Host Purine Metabolism in Intes-tine through Gut Microbiota and Ameliorates Experimental Colitis. Theranostics, 10, 10665-10679. https://doi.org/10.7150/thno.43528
|
[31]
|
Wang, L.M., Wang, P., Teka, T., et al. (2020) 1H NMR and UHPLC/Q-Orbitrap-MS-Based Metabolomics Combined with 16S rRNA Gut Microbiota Analysis Revealed the Poten-tial Regulation Mechanism of Nuciferine in Hyperuricemia Rats. Journal of Agricultural and Food Chemistry, 68, 14059-14070. https://doi.org/10.1021/acs.jafc.0c04985
|
[32]
|
王雨, 林志健, 边猛, 等. 维药菊苣提取物对高尿酸血症状态下肠道屏障的影响[J]. 中华中医药杂志, 2018, 33(5): 1718-1723.
|
[33]
|
王雨, 林志健, 张冰. 中药菊苣改善氧化应激性炎症介导的“肠-肾”尿酸排泄研究[J]. 中华中医药杂志, 2020, 35(5): 2552-2557.
|
[34]
|
刘秋萍, 余怡然, 李海昌, 温成平, 何志兴. 祛浊通痹方对尿酸代谢异常模型大鼠肠道菌群的调节作用[J]. 中华中医药杂志, 2019, 34(4): 1722-1726.
|